Soluble Fermentable Dietary Fibre (Pectin) Decreases Caloric Intake, Adiposity and Lipidaemia in High-Fat Diet-Induced Obese Rats

Funding: This work was funded by the Scottish Government Rural and Environment Science and Analytical Services Division. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Peer reviewedPublisher PD

Dose-dependent effects of a soluble dietary fibre (pectin) on food intake, adiposity, gut hypertrophy and gut satiety hormone secretion in rats

Acknowledgments We thank Donna Wallace and Animal House staff at the Rowett Institute of Nutrition and Health for the daily care of experimental rats and for the body weight, food intake and MRI measurements.Peer reviewedPublisher PD

Different types of soluble fermentable dietary fibre decrease food intake, body weight gain and adiposity in young adult male rats

We thank Donna Wallace and the Rowett Animal House staff for the daily care of experimental rats, body weight and food intake measurements and MRI scanning, Vivien Buchan and Donna Henderson of the Rowett Analytical Department for proximate analyses and SCFA GC, and Andrew Chappell for conducting the beta-glucan analysis. This research was funded by the Scottish Government’s Rural and Environment Science and Analytical Services Division.Peer reviewedPublisher PD

LMDA Review, volume 8, issue 1 (sic)

Contents include: From the President, A Note on this Newsletter, A Call for Volunteers, Conference News: ATHE and LMDA, LMDA at ATHE: The Probable Conversion of a Skeptic, 1998 LMDA Conference, The 1997 LMDA Conference at Yale University: Looking Back, To My Colleagues (II), LMDA Advocacy Caucus, and Regional Vice-Presidents. Issue editor: Michele Volanskyhttps://soundideas.pugetsound.edu/lmdareview/1014/thumbnail.jp

LMDA Review, volume 8, issue 1

Contents include: From the President, Jayme Koszyn, Blaulapalooza in Imilwaukee, Notes from Avignon: Diary of a Francophile Theatre Junkie, 1997 Conference News, Canadian Regional News, A Letter to My Colleagues from Lynn M. Thomson, ATHR Group Meets, Proposes Panel for New \u27Turgs, Regional News: The Chicago Gang Meets Again, Member News, and Regional VP\u27s.https://soundideas.pugetsound.edu/lmdareview/1015/thumbnail.jp

Effects of Dietary Fibre (Pectin) and/or Increased Protein (Casein or Pea) on Satiety, Body Weight, Adiposity and Caecal Fermentation in High Fat Diet-Induced Obese Rats

We thank the University of Aberdeen MRF staff for the daily care of experimental rats, body weight, food intake and MRI measurements. We also thank the Analytical Department of the Rowett Institute for Nutrition and Health for the proximate analyses, glucose determinations and SCFA GC. Funding: This work was funded by the Scottish Government Rural and Environment Science and Analytical Services Division. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Peer reviewedPublisher PD

Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care 'REACT'.

INTRODUCTION: Hyperglycaemia is common in the very preterm infant and has been associated with adverse outcomes. Preventing hyperglycaemia without increasing the risk of hypoglycaemia has proved challenging. The development of real-time continuous glucose monitors (CGM) to inform treatment decisions provides an opportunity to reduce this risk. This study aims to assess the feasibility of CGM combined with a specifically designed paper guideline to target glucose control in the preterm infant. METHODS AND ANALYSES: The Real Time Continuous Glucose Monitoring in Neonatal Intensive Care (REACT) trial is an international multicentre randomised controlled trial. 200 preterm infants ≤1200 g and ≤24 hours of age will be randomly allocated to either real-time CGM or standard care (with blinded CGM data collection). The primary outcome is time in target 2.6-10 mmol/L during the study intervention assessed using CGM. Secondary outcomes include efficacy relating to glucose control, utility including staff acceptability, safety outcomes relating to incidence and prevalence of hypoglycaemia and health economic analyses. ETHICS AND DISSEMINATION: The REACT trial has been approved by the National Health Service Health Research Authority National Research Ethics Service Committee East of England (Cambridge Central); Medical Ethics Review Committee, VU University Medical Centre, Amsterdam, The Netherlands and the Research Ethics Committee, Sant Joan de Déu Research Foundation, Barcelona, Spain. Recruitment began in July 2016 and will continue until mid-2018. The trial has been adopted by the National Institute of Health Research Clinical Research Network portfolio (ID: 18826) and is registered with anInternational Standard Randomised Control Number (ISRCTN registry ID: 12793535). Dissemination plans include presentations at scientific conferences, scientific publications and efforts at stakeholder engagement. TRIAL REGISTRATION NUMBER: ISRCTN12793535; Pre-results

LMDA Review, volume 11, issue 1

Contents include: Advocacy Guidelines,LMDA Members Meet with the NEA, Update The Elliot Hayes Award,Update Script Exchange, Presentation Of Elliott Hayes Award to Rebecca Rugg, To Lynn Thomson, Conference Panels and Sessions, Conversations About Digital Dramaturgy, Key Note, Dramaturg As Generator, Multi-Authorship: Too Many Cooks?, Desperately Seeking Research, On Copyright, The Dramaturg As Advocate For The Arts On City, State/Provincial, And National Levels, Entrances And Exits, The (New Play) Workshop\u27s The Thing, Anne Cattaneo On Commissioning New Work, LMDA Regions And VPs, News From Canada, News from Baltimore, News from Chicago, The Past Two Years, and On, Notes to Fellow LMDA Members, Spotlight on Early Career Dramturgs, Dramaturgy Opening Arena Stage, Internship at the Women\u27s Project, Literary Residency in New York, Dramaturgy/Literary Management Internship at Arena Stage, Job Opening at UCSD, A Note to LMDA Members, Unity Fest 2001 Call for Scripts, Call for Directors, Actors, Dramaturgs, and Call for Updates to the LMDA Guide to Programs in Dramaturgy.https://soundideas.pugetsound.edu/lmdareview/1022/thumbnail.jp

Real-time continuous glucose monitoring in preterm infants (REACT): an international, open-label, randomised controlled trial.

BACKGROUND: Hyperglycaemia and hypoglycaemia are common in preterm infants and have been associated with increased risk of mortality and morbidity. Interventions to reduce risk associated with these exposures are particularly challenging due to the infrequent measurement of blood glucose concentrations, with the potential of causing more harm instead of improving outcomes for these infants. Continuous glucose monitoring (CGM) is widely used in adults and children with diabetes to improve glucose control, but has not been approved for use in neonates. The REACT trial aimed to evaluate the efficacy and safety of CGM in preterm infants requiring intensive care. METHODS: This international, open-label, randomised controlled trial was done in 13 neonatal intensive care units in the UK, Spain, and the Netherlands. Infants were included if they were within 24 h of birth, had a birthweight of 1200 g or less, had a gestational age up to 33 weeks plus 6 days, and had parental written informed consent. Infants were randomly assigned (1:1) to real-time CGM or standard care (with masked CGM for comparison) using a central web randomisation system, stratified by recruiting centre and gestational age (<26 or ≥26 weeks). The primary efficacy outcome was the proportion of time sensor glucose concentration was 2·6-10 mmol/L for the first week of life. Safety outcomes related to hypoglycaemia (glucose concentrations <2·6 mmol/L) in the first 7 days of life. All outcomes were assessed on the basis of intention to treat in the full analysis set with available data. The study is registered with the International Standard Randomised Control Trials Registry, ISRCTN12793535. FINDINGS: Between July 4, 2016, and Jan 27, 2019, 182 infants were enrolled, 180 of whom were randomly assigned (85 to real-time CGM, 95 to standard care). 70 infants in the real-time CGM intervention group and 85 in the standard care group had CGM data and were included in the primary analysis. Compared with infants in the standard care group, infants managed using CGM had more time in the 2·6-10 mmol/L glucose concentration target range (mean proportion of time 84% [SD 22] vs 94% [11]; adjusted mean difference 8·9% [95% CI 3·4-14·4]), equivalent to 13 h (95% CI 5-21). More infants in the standard care group were exposed to at least one episode of sensor glucose concentration of less than 2·6 mmol/L for more than 1 h than those in the intervention group (13 [15%] of 85 vs four [6%] of 70). There were no serious adverse events related to the use of the device or episodes of infection. INTERPRETATION: Real-time CGM can reduce exposure to prolonged or severe hyperglycaemia and hypoglycaemia. Further studies using CGM are required to determine optimal glucose targets, strategies to obtain them, and the potential effect on long-term health outcomes. FUNDING: National Institute for Health Research Efficacy and Mechanisms Evaluation Programme.NIHR EM